Mast Therapeutics Inc (NYSEMKT:MSTX) is in a strong position on the back of two successful Phase II studies for its pipeline drug AIR001, …
Maxim analyst Jason Kolbert reiterates a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX) following an announcement of first patient enrollment in …
Mast Therapeutics Inc (NYSEMKT:MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure, today reported that the first …
Mast Therapeutics Inc (NYSEMKT:MSTX) just announced to frustrated investors that EPIC results for its Sickle Cell pipeline drug vepoloxamer are pushed back now …
Maxim analyst Jason McCarthy comments on Mast Therapeutics Inc (NYSEMKT:MSTX) ahead of EPIC study data for the investigation of Sickle Cell Disease (SCD), …
Shares of Mast Therapeutics Inc (NYSEMKT:MSTX) are down 15% on Tuesday after the company disclosed that it now expects top-line results from the Phase 3 EPIC …
What does the future hold for Mast Therapeutics Inc (NYSEMKT:MSTX)? Roth Capital analyst Michael Higgins weighs in on the biotech company, providing investors a summary …
In a research note published Tuesday, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX), with a price target …
New insights emerge in the biotech sector as Galena Biopharma Inc (NASDAQ:GALE) presented an update on GALE-301 at the American Society of Clinical Oncology (ASCO) 2016 …
There’s good news all around as Exelixis, Inc. (NASDAQ:EXEL) releases promising data in an attempt to expand the indication of one of its …
